-
Published 3/31/2025
Fontana M, Berk JL, Drachman B, Garcia-Pavia P, Hanna M, Lairez O, Witteles R. Changing Treatment Landscape in Transthyretin Cardiac Amyloidosis. Circ Heart Fail. 2025 Mar 31; e012112. PMID: 40160093.
-
Published 3/1/2025
Adams D, Wixner J, Polydefkis M, Berk JL, Conceição IM, Dispenzieri A, Peltier A, Ueda M, Bender S, Capocelli K, Jay PY, Yureneva E, Obici L. Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy: A Randomized Clinical Trial With Open-Label Extension. JAMA Neurol. 2025 Mar 01; 82(3):228-236. PMID: 39804640.
-
Published 2/3/2025
Conceição I, Berk JL, Weiler M, Kowacs PA, Dasgupta NR, Khella S, Chao CC, Attarian S, Kwoh TJ, Jung SW, Chen J, Viney NJ, Yu RZ, Gertz M, Masri A, Cruz MW, Coelho T. Correction: Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform. J Neurol. 2025 Feb 03; 272(2):182. PMID: 39899052.
-
Published 11/17/2024
Wixner J, Berk JL, Adams D, Polydefkis M, Conceição I, Attarian S, Gillmore JD, Dyck PJB, Folkvaljon F, Zhou W, Chen J, Viney NJ, Kwoh TJ, Coelho T, Waddington-Cruz M. Effects of eplontersen on symptoms of autonomic neuropathy in hereditary transthyretin-mediated amyloidosis: secondary analysis from the NEURO-TTRansform trial. Amyloid. 2025 Mar; 32(1):29-38. PMID: 39552152.
-
Published 11/17/2024
Folkvaljon F, Gertz M, Gillmore JD, Khella S, Masri A, Maurer MS, Cruz MW, Wixner J, Chen J, Reicher B, Kwoh J, Yarlas A, Berk JL. Estimating Meaningful Differences in Measures of Neuropathic Impairment, Health-Related Quality of Life, and Nutritional Status in Patients With Hereditary Transthyretin Amyloidosis. Muscle Nerve. 2025 Jan; 71(1):96-107. PMID: 39552102.